Journal: BioMed Research International
Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma
doi: 10.1155/2019/3210324
Figure Lengend Snippet: Expression of IGFBP5 in Caki-2 cell line. (a) Expression of VEGFA after inhibited by siRNA ( n = 3). The fold change is 3.1 ( P < 0.01). (b) Expression of TGF- β after inhibited by siRNA ( n = 3). The fold change is 5.4 ( P < 0.01). (c) Expression of IGFBP5 after VEGFA and TGF- β blocked by siRNA ( n = 3). IGFBP5 was downregulated by 2.6-fold and 4.0 fold respectively ( P < 0.01). (d) Expression of IGFBP5 after stimulated by VEGF 165 and TGF- β ( n = 3). IGFBP5 was upregulated by 2.8-fold and 6.2-fold respectively ( P < 0.01). (e) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of IGFBP5 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of IGFBP5 knockdown group is lower than normal control group ( P < 0.05). (f) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of VEGF 165 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of TGF- β stimulation group is lower than normal control group ( P < 0.05). ( n = 3) (∗, p < 0.05;∗∗, p < 0.01;∗∗∗, p < 0.001).
Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).
Techniques: Expressing, MTT Assay, Control, Knockdown